Wave Life Sciences（股票代码：WVE）今日盘中大涨91.72%，创下显著涨幅。
消息面上，公司公布了Wve-007（Inhbe）针对肥胖症的1期Inlight试验的积极中期数据。数据显示，单剂量在三个月内实现了体脂肪降低，效果与GLP-1药物相似，且未观察到肌肉流失。这一结果增强了市场对公司肥胖症治疗药物的信心。
Wve-007是一种针对INHBE基因的RNA编辑疗法，旨在通过调节代谢途径减少体脂肪。此次公布的积极数据为后续临床试验和潜在商业化奠定了基础，进一步推动了投资者对公司的乐观预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.